Osteopathic Sympathetic Harmonization and Depression

April 7, 2021 updated by: Ömer Osman PALA, Cumhuriyet University

Assessment of Effectiveness of the Osteopathic Sympathetic Harmonization Applications on the Sympathetic Nervous System and the HPA Axis With Depression Diagnosed Adolescents: A Double-blind, Placebo-controlled, Randomized Study

Depression appears to be resistant to the available pharmacological treatments. Autonomic responses accompanied by any psychological stress are sympathetic nervous system (SNS) and neuroendocrine responses are formed by hypothalamus-pituitary-adrenal (HPA) axis. The purpose of this study is; assessment of effectiveness of osteopathic approach on sympathetic nervous system and HPA axis in adolescents with depression.

Study Overview

Detailed Description

Depression diagnosed and volunteer to participate 39 cases who between the ages of 15-21 included. All participants were recruited and randomly assigned into two groups, the osteopathy group (OG) and the placebo group (PG). Stimulation on the sympathetic truncus and prevertebral ganglia were performed in the OG group. The stimulation of the PG group was performed with a lighter touch and a shorter duration in similar areas. Each participant was filled in the demographic data form, Beck Depression Scale and State and Trait Anxiety Inventory (STAI Form - 1 and Form - 2) before the application. Emotional state visual analog scale and STAI Form - 1 was filled and blood pressure and pulse measurement were made and saliva sample was taken before application, immediately after application and 20 minutes after application.

Study Type

Interventional

Enrollment (Actual)

39

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Si̇vas, Turkey, 58140
        • Sivas Cumhuriyet University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 21 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • To be diagnosed with clinical depression by a psychiatrist according to The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria
  • Volunteering to participate in the study

Exclusion Criteria:

  • Fever over 38.5
  • Acute injury or infection
  • Rib fracture
  • Cardiac arrhythmia
  • Using drugs that affect cortisol levels (oral contraceptives, hormonal drugs, antidepressants, antipsychotics etc.)
  • Being pregnant, premenstrual or in the menstrual period for female participants

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Osteopathy Group
Stimulation on the sympathetic truncus and prevertebral ganglia
Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
Sham Comparator: Control Group
Stimulation on similar areas with lighter touch and shorter duration
Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Beck Depression Inventory (BDI)
Time Frame: Before intervention
The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.
Before intervention
The State-Trait Anxiety Inventory (STAI) Form - 1
Time Frame: Before intervention
The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety. It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It also is often used in research as an indicator of caregiver distress.
Before intervention
Change from Baseline The State-Trait Anxiety Inventory (STAI) Form - 2 at 20 minutes
Time Frame: Before intervention, immediately after the intervention, 20 minutes after the intervention
The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety. It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It also is often used in research as an indicator of caregiver distress.
Before intervention, immediately after the intervention, 20 minutes after the intervention
Change from Baseline Heart rate and blood pressure measurements at 20 minutes
Time Frame: Before intervention, immediately after the intervention, 20 minutes after the intervention
Heart rate (beats per minute) and blood pressure (mm/Hg) were measured with automatic blood pressure monitor (the Microlife BP 3BT0-A). It is a clinically validated and 1-star automatic blood pressure monitor
Before intervention, immediately after the intervention, 20 minutes after the intervention
Change from Baseline Salivary Biomarkers at 20 minutes
Time Frame: Before intervention, immediately after the intervention, 20 second after the intervention
Salivary a-amylase and cortisol levels were measured for each sample. These biomarkers were analysed Enzyme-Linked Immunosorbent Assay.
Before intervention, immediately after the intervention, 20 second after the intervention
Demographic data
Time Frame: Before intervention
Sex; male or female
Before intervention
Demographic data
Time Frame: Before intervention
Age; years
Before intervention
Demographic data
Time Frame: Before intervention
Height (m); weight (kg); body mass index (kg/m2)
Before intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Omer Osman PALA, PhD, Cumhuriyet University, Faculty of Health Sciences, Physiotherapy and Rehabilitation
  • Principal Investigator: Seyit CITAKER, Prof, Gazi University, Faculty of Health Sciences, Physiotherapy and Rehabilitation
  • Principal Investigator: Esra GUNEY, Assoc. Prof, Gazi University, Faculty of Medicine, Child and Adolescent Psychiatry
  • Principal Investigator: Aylin SEPICI DINCEL, Prof, Gazi University, Faculty of Medicine, Medical Biochemistry
  • Principal Investigator: Güner Melike GUVELI, MD, Gazi University, Faculty of Medicine, Child and Adolescent Psychiatry
  • Principal Investigator: Burak ARSLAN, MD, Gazi University, Faculty of Medicine, Medical Biochemistry

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 11, 2017

Primary Completion (Actual)

March 23, 2018

Study Completion (Actual)

June 5, 2018

Study Registration Dates

First Submitted

April 4, 2021

First Submitted That Met QC Criteria

April 7, 2021

First Posted (Actual)

April 9, 2021

Study Record Updates

Last Update Posted (Actual)

April 9, 2021

Last Update Submitted That Met QC Criteria

April 7, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E-16-1106

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Sharing Time Frame

January 1, 2022

IPD Sharing Supporting Information Type

  • Clinical Study Report (CSR)
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteopathic Manipulative Treatment

Clinical Trials on Osteopathic sympathic harmonization

3
Subscribe